Skip to main content

Piper Calls Valeant Management 'Overly Rosy,' Cuts Price Target To $10

Management of Valeant Pharmaceuticals is taking an "overly rosy" long-term view of the business, Piper Jaffray analyst David Amsellem tells investors in a research note following the company's Q4 results.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.